Here's What Key Metrics Tell Us About AdvanSix (ASIX) Q4 Earnings

Core Insights - AdvanSix reported revenue of $382.21 million for Q4 2023, a year-over-year decline of 5.4$0.10 compared to $1.27 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of$335.8 million by 13.82%, and the EPS also surpassed the consensus estimate of -$0.12 by 16.67$78.25 million, exceeding the average estimate of $74.69 million from three analysts [2] - Sales of Ammonium Sulfate were$108.69 million, slightly above the estimated $108.15 million [2] - Sales of Chemical Intermediates amounted to$112.76 million, significantly higher than the average estimate of $83.67 million [2] - Sales of Caprolactam were$82.51 million, compared to the average estimate of $65.35 million [2] Stock Performance - AdvanSix shares returned +8.9% over the past month, outperforming the Zacks S&P 500 composite's +5.3% change [2] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [2]